Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial

JAMA

Volumn 311, Issue 1, 2014, Pages 62-73

  Heldman, Alan W ^a   DiFede, Darcy L ^a   Fishman, Joel E ^a   Zambrano, Juan P ^a   Trachtenberg, Barry H ^a   Karantalis, Vasileios ^a   Mushtaq, Muzammil ^a   Williams, Adam R ^a   Suncion, Viky Y ^a   McNiece, Ian K ^a,e   Ghersin, Eduard ^a   Soto, Victor ^a   Lopera, Gustavo ^a,b   Miki, Roberto ^a   Willens, Howard ^a   Hendel, Robert ^a   Mitrani, Raul ^a   Pattany, Pradip ^f   Feigenbaum, Gary ^a   Oskouei, Behzad ^a   Byrnes, John ^a   Lowery, Maureen H ^a   Sierra, Julio ^a   Pujol, Mariesty V ^a   Delgado, Cindy ^a   Gonzalez, Phillip J ^a   Rodriguez, Jose E ^a   Bagno, Luiza Lima ^a   Rouy, Didier ^c   Altman, Peter ^c   Foo, Cheryl Wong Po ^c   Da Silva, Jose ^a   Anderson, Erica ^d   Schwarz, Richard ^a   Mendizabal, Adam ^d   Hare, Joshua M ^a   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GRECC Miami Veterans Affairs Healthcare System   (United States)

^c Biocardia Corporation   (United States)

^d EMMES CORPORATION   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MD Anderson Cancer Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

AGED; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; STROKE; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84891941987     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282909     Document Type: Article

References (43)

1. Assmus B, Honold J, Schächinger V, et al. Transcoronary transplantation of progenitor cells aftermyocardial infarction. N Engl J Med. 2006;355(12):1222-1232.
2. de la Fuente LM, Stertzer SH, Argentieri J, et al. Transendocardial autologous bone marrow in chronicmyocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study). Am Heart J. 2007;154(1):79.e1-79.e7.
3. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation. 2006;114(1)(suppl):I101-I107.
4. Leistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011;100(10):925-934.
5. Perin EC, Willerson JT, Pepine CJ, et al Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717-1726.
6. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429): 141-148.
7. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277-2286.
8. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011;108(7):792-796.
9. Losordo DW, Henry TD, Davidson C, et al; ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428-436.
10. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.
11. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575-1578.
12. Hatzistergos KE, Blum A, Ince T, Grichnik JM, Hare JM. What is the oncologic risk of stem cell treatment for heart disease? Circ Res. 2011;108(11):1300-1303.
13. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109(8):923-940.
14. Trachtenberg B, Velazquez DL, Williams AR, et al. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011;161(3):487-493.
15. Mak GS, Truong QA. Cardiac CT: imaging of and through cardiac devices. Curr Cardiovasc Imaging Rep. 2012;5(5):328-336.
16. Junttila MJ, Fishman JE, Lopera GA, et al. Safety of serial MRI in patients with implantable cardioverter defibrillators. Heart. 2011;97(22):1852-1856.
17. Da Silva JS, Hare JM. Cell-based therapies for myocardial repair: emerging role for bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of the chronically injured heart. Methods Mol Biol. 2013;1037:145-163.
18. Amado LC, Schuleri KH, Saliaris AP, et al. Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J Am Coll Cardiol. 2006;48(10):2116-2124.
19. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial [published correction appears in JAMA. 2013;310(7):750]. JAMA. 2012;308(22): 2369-2379.
20. Lamas GA, Vaughan DE, Parisi AF, Pfeffer MA. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acutemyocardial infarction. Am J Cardiol. 1989;63(17):1167-1173.
21. Hare JM, Bolli R, Cooke JP, et al Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation. 2013;127(15):1630-1635.
22. Choi SI, George RT, Schuleri KH, Chun EJ, Lima JA, Lardo AC. Recent developments in wide-detector cardiac computed tomography. Int J Cardiovasc Imaging. 2009;25(suppl 1):23-29.
23. Bolli R, Chugh AR, D'Amario D, et al. Cardiac Stem Cells in Patients With Ischaemic Cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806): 1847-1857.
24. Kinkaid HY, Huang XP, Li RK, Weisel RD. What's new in cardiac cell therapy? allogeneic bone marrow stromal cells as "universal donor cells." J Card Surg. 2010;25(3):359-366.
25. Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011;50(2):258-265.
26. Suncion VY, Schulman IH, Hare JM. The role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells-Transl Med. 2012;1(2):29-35.
27. Telukuntla KS, Suncion VY, Schulman IH, Hare JM. The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc. 2013;2(5):e000338.
28. Hamamoto H, Gorman JH III, Ryan LP, et al. Allogeneicmesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann Thorac Surg. 2009;87(3):794-801.
29. Lee ST, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol. 2011;57(4):455-465.
30. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneicmesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009;106(33):14022-14027.
31. Schuleri KH, Amado LC, Boyle AJ, et al. Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiol Heart Circ Physiol. 2008;294(5):H2002-H2011.
32. Williams AR, Suncion VY, McCall F, et al. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc. 2013;2(3):e000140.
33. Williams AR, Hatzistergos KE, Addicott B, et al. Enhanced effect of combining human cardiac stem cells and bone marrowmesenchymal stem cells to reduce infarct size and to restore cardiac function aftermyocardial infarction. Circulation. 2013;127(2):213-223.
34. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol. 2012;303(3):H256-H270.
35. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367(9505):113-121.
36. Bello D, Einhorn A, Kaushal R, et al. Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease. Magn Reson Imaging. 2011;29(1):50-56.
37. Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation. 2004;110(11)(suppl 1):II213-II218.
38. Silva GV, Litovsky S, Assad JA, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. 2005;111(2):150-156.
39. Zhou Y, Wang S, Yu Z, Hoyt RF Jr, Qu X, Horvath KA. Marrow stromal cells differentiate into vasculature after allogeneic transplantation into ischemicmyocardium. Ann Thorac Surg. 2011;91(4):1206-1212.
40. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrowmesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):913-922.
41. Schuleri KH, Centola M, Choi SH, et al. CT for evaluation ofmyocardial cell therapy in heart failure: a comparison with CMR imaging. JACC Cardiovasc Imaging. 2011;4(12):1284-1293.
42. Mahnken AH, Koos R, Katoh M, et al. Assessment of myocardial viability in reperfused acutemyocardial infarction using 16-slice computed tomography in comparison to magnetic resonance imaging. J Am Coll Cardiol. 2005;45(12):2042-2047.
43. Nihoyannopoulos P, Vanoverschelde JL. Myocardial ischaemia and viability: the pivotal role of echocardiography. Eur Heart J. 2011;32(7):810-819.